3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
Gastrointestinal
3
Thoracic
2
Head & Neck
2
Sarcoma
1
Other solid neoplasm
1
NET
1
Gynecologic
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Somatostatinoma
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Insulinoma
1
Glucagonoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gastrinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Islet Cell
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Everolimus
5
pembrolizumab
2
cabozantinib
2
Trastuzumab
2
Nivolumab
2
vatalanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
temsirolimus
1
spartalizumab
1
romidepsin
1
regorafenib
1
pentetreotide
1
guadecitabine
1
fostamatinib
1
exemestane
1
entrectinib
1
entinostat
1
belzutifan
1
avelumab
1
alectinib
1
Vinorelbine
1
Sirolimus
1
Rosiglitazone
1
Ritonavir
1
Radiotherapy
1
Quality of Life
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
Nephrectomy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
regorafenib
×
Endocrine
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled